Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial

MT Newswires Live2024-12-31

(Updates with stock price movement in the headline and first paragraph)

ADC Therapeutics (ADCT) gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026," said Chief Medical Officer Mohamed Zaki in a statement late Monday.

The stock was up 0.8% in recent trading.

Price: 1.91, Change: +0.01, Percent Change: +0.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500892641?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-01 03:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500892641","market":"hk","top_or_hot":-1,"title":"Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial","media":"MT Newswires Live","content":"<html><body><p> (Updates with stock price movement in the headline and first paragraph)</p><p>ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ADCT) gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.</p><p>\"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026,\" said Chief Medical Officer Mohamed Zaki in a statement late Monday.</p><p>The stock was up 0.8% in recent trading.</p><p>Price: 1.91, Change: +0.01, Percent Change: +0.53</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-01 03:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> (Updates with stock price movement in the headline and first paragraph)</p><p>ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ADCT) gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.</p><p>\"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026,\" said Chief Medical Officer Mohamed Zaki in a statement late Monday.</p><p>The stock was up 0.8% in recent trading.</p><p>Price: 1.91, Change: +0.01, Percent Change: +0.53</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500892641","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500892641","pubTimestamp":1735672550,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ADC Therapeutics  gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.\"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026,\" said Chief Medical Officer Mohamed Zaki in a statement late Monday.The stock was up 0.8% in recent trading.Price: 1.91, Change: +0.01, Percent Change: +0.53","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","ADCT":"ADC Therapeutics SA","SSI":"Stage Stores Inc","BK4080":"零售业房地产投资信托","ADC":"艾格里房产","BK4231":"零售房地产信托"},"translate_title":"更新：ADC股价在公司完成后期Zynlonta组合试验招募后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"ADCT":0.9,"SSI":1},"content_text":"(Updates with stock price movement in the headline and first paragraph)ADC Therapeutics (ADCT) gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.\"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026,\" said Chief Medical Officer Mohamed Zaki in a statement late Monday.The stock was up 0.8% in recent trading.Price: 1.91, Change: +0.01, Percent Change: +0.53","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500892641"}